目的 探究愈風(fēng)寧心滴丸聯(lián)合單硝酸異山梨酯-治療冠心病心絞痛的臨床效果。方法 選取2020年1月—2022年12月于北京市隆福醫(yī)院進行治療的130例冠心病心絞痛患者進行回顧性研究，按照不同治療方案分為對照組和治療組，每組各65例。對照組患者飯后溫水吞服單硝酸異山梨酯片，1片/次，2次/d。治療組患者除使用單硝酸異山梨酯片外，還口服愈風(fēng)寧心滴丸，12丸/次，3次/d，單硝酸異山梨酯片用法用量與對照組一致。兩組均連續(xù)治療8周。觀察兩組的臨床療效和心絞痛癥狀改善情況，比較兩組心功能指標(biāo)、血管內(nèi)皮功能指標(biāo)、氧化應(yīng)激指標(biāo)和炎癥反應(yīng)指標(biāo)。結(jié)果 治療后，治療組總有效率是95.38%，顯著高于對照組的84.62%，具有統(tǒng)計學(xué)差異（P＜0.05）。治療后，兩組心絞痛發(fā)作次數(shù)、疼痛評分均顯著降低，而6 min步行距離（6MWD）顯著增加（P＜0.05）；治療后，治療組心絞痛發(fā)作次數(shù)、疼痛評分低于對照組，6WMD水平高于對照組（P＜0.05）。治療后，兩組心排血量（CO）、左心室射血分數(shù)（EF）水平顯著升高（P＜0.05）；治療后，治療組CO、EF水平高于對照組（P＜0.05）。治療后，兩組內(nèi)皮細胞特異性分子-1（ESM-1）、血管緊張素II（AngII）水平較同組治療前顯著降低，而一氧化氮合酶（NOS）水平高于治療前（P＜0.05）；治療后，治療組ESM-1、AngII水平低于對照組，NOS水平高于對照組（P＜0.05）。治療后，兩組總抗氧化能力（TAOC）、晚期糖基化終產(chǎn)物（AGEs）、淀粉樣蛋白A（SAA）、白細胞介素-13（IL-13）水平較同組治療前顯著降低（P＜0.05）；治療后，治療組TAOC、AGEs、SAA、IL-13水平低于對照組（P＜0.05）。結(jié)論 愈風(fēng)寧心滴丸聯(lián)合單硝酸異山梨酯-治療冠心病心絞痛可明顯改善患者心絞痛癥狀，改善心功能及內(nèi)皮功能，減輕氧化應(yīng)激、炎癥反應(yīng)，臨床療效較理想。

Objective To explore the clinical effect of Yufeng Ningxin Dripping Pills combined with isosorbide mononitrate in treatment of angina pectoris. Methods A retrospective study was conducted on 130 patients with angina pectoris treated in Beijing Longfu Hospital from January 2020 to December 2022. They were divided into control group and treatment group according to different treatment protocols, with 65 cases in each group. Patients in control group swallowed Isosorbide Mononitrate Tablets with warm water after meals, 1 tablet/time, twice daily. In addition to Isosorbide Mononitrate Tablets, patients in treatment group were also given Yufengningxin Dropping Pills, 12 pills/time, 3 times daily. The usage and dosage of Isosorbide Mononitrate Tablets were consistent with those in control group. Both groups were treated continuously for 8 weeks. The clinical efficacy and improvement of angina pectoris symptoms in two groups were observed, and the indexes of cardiac function, vascular endothelial function, oxidative stress and inflammatory response were compared between two groups. Results After treatment, the total effective rate of the treatment group was 95.38%, which was significantly higher than that of the control group (84.62%), with statistical difference (P < 0.05). After treatment, the frequency of angina pectoris attack and pain score were significantly decreased in both groups, but 6MWD was significantly increased (P < 0.05). After treatment, the angina attack frequency and pain score in treatment group were lower than those in control group, and the level of 6WMD was higher than that in control group (P < 0.05). After treatment, the levels of CO and EF in two groups were significantly increased (P < 0.05). After treatment, the levels of CO and EF in treatment group were higher than those in control group (P < 0.05). After treatment, the levels of ESM-1 and AngII in two groups were significantly lower than before treatment, but the levels of NOS were higher than before treatment (P < 0.05). After treatment, ESM-1 and AngII levels in treatment group were lower than those in control group, but NOS levels were higher than those in control group (P < 0.05). After treatment, the levels of TAOC, AGEs, SAA, and IL-13 in two groups were significantly decreased compared with those before treatment (P < 0.05). After treatment, the levels of TAOC, AGEs, SAA, and IL-13 in treatment group were lower than those in control group (P < 0.05). Conclusion Yufeng Ningxin Dripping Pills combined with isosorbide mononitrate in treatment of angina pectoris can significantly improve the symptoms of angina pectoris, and can improve cardiac function and endothelial function, reduce oxidative stress and inflammation, and the clinical efficacy is satisfactory.

R972

內(nèi)蒙古自治區(qū)衛(wèi)生健康中醫(yī)藥(蒙醫(yī)藥)科技計劃項目（ZMY-2024211）